Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Sodium-dependent serotonin transporter (SERT) and Sodium-dependent noradrenaline transporter (NET) are integral membrane proteins belonging to the solute carrier family 6 (SLC6) (UniProt P31645, P23975). They play a critical role in terminating the action of serotonin and norepinephrine in the synaptic cleft by facilitating their reuptake into the presynaptic neuron (StatPearls, "Serotonin Norepinephrine Reuptake Inhibitors"). This dual transport system is essential for regulating mood, emotional behavior, and descending pain inhibitory pathways in the central nervous system (PubMed, PMID: 24551567). Dysregulation of these transporters is strongly linked to the pathophysiology of major depressive disorder, anxiety disorders, and chronic pain conditions (NIH, "Depression"). Drugs that simultaneously target both SERT and NET, known as serotonin-norepinephrine reuptake inhibitors (SNRIs), are widely used to treat these conditions by increasing the availability of both neurotransmitters (PubChem). By enhancing serotonergic and noradrenergic signaling, these therapies provide both antidepressant effects and analgesic properties. However, the modulation of NET can lead to cardiovascular side effects such as increased heart rate and blood pressure (FDA, "Cymbalta Label"). Therapeutic success often depends on the specific affinity ratio for each transporter, which varies among different SNRI compounds.
SNRIs bind to the substrate binding sites of both SERT and NET, competitively inhibiting the transport of serotonin and norepinephrine back into the presynaptic terminal (StatPearls). This leads to an accumulation of these monoamines in the synaptic cleft, enhancing their interaction with post-synaptic receptors and modulating neural circuits involved in mood and pain (PubMed, PMID: 15159677).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium-dependent serotonin transporter (SERT) and Sodium-dependent noradrenaline transporter (NET) (SERT/NET).